Reduced-intensity fludarabine/melphalan confers similar survival to busulfan/fludarabine myeloablative regimens for patients with acute myeloid leukemia and myelodysplasia (Q90059956)

From Wikidata

Jump to navigation Jump to search

scientific article published on 05 March 2020

Language	Label	Description	Also known as
English	Reduced-intensity fludarabine/melphalan confers similar survival to busulfan/fludarabine myeloablative regimens for patients with acute myeloid leukemia and myelodysplasia	scientific article published on 05 March 2020

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32133897%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

Reduced-intensity fludarabine/melphalan confers similar survival to busulfan/fludarabine myeloablative regimens for patients with acute myeloid leukemia and myelodysplasia (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32133897%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

Elizabeth DiMaggio

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32133897%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

author name string

Jun-Min Zhou

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32133897%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

Ryan Caddell

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32133897%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

Rebecca Tombleson

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32133897%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

Janelle Perkins

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32133897%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

Claudio Anasetti

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32133897%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

Farhad Khimani

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32133897%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

Joseph Pidala

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32133897%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

Taiga Nishihori

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32133897%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

Lia Perez

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32133897%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

Brian Betts

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32133897%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

Hugo F Fernandez

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32133897%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

Asmita Mishra

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32133897%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

publication date

5 March 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32133897%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32133897%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

1-10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32133897%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

1994 Consensus Conference on Acute GVHD Grading

1 reference

https://pubmed.ncbi.nlm.nih.gov/32133897

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics

1 reference

https://pubmed.ncbi.nlm.nih.gov/32133897

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

International scoring system for evaluating prognosis in myelodysplastic syndromes

1 reference

https://pubmed.ncbi.nlm.nih.gov/32133897

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

1 reference

https://pubmed.ncbi.nlm.nih.gov/32133897

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report

1 reference

https://pubmed.ncbi.nlm.nih.gov/32133897

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse

1 reference

https://pubmed.ncbi.nlm.nih.gov/32133897

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/32133897

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research

1 reference

https://pubmed.ncbi.nlm.nih.gov/32133897

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Defining the intensity of conditioning regimens: working definitions

1 reference

https://pubmed.ncbi.nlm.nih.gov/32133897

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis

1 reference

https://pubmed.ncbi.nlm.nih.gov/32133897

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hematopoietic stem cell transplantation for MDS.

1 reference

https://pubmed.ncbi.nlm.nih.gov/32133897

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Allogeneic stem cell transplantation for acute myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/32133897

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/32133897

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/32133897

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A disease risk index for patients undergoing allogeneic stem cell transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/32133897

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Revised international prognostic scoring system for myelodysplastic syndromes

1 reference

https://pubmed.ncbi.nlm.nih.gov/32133897

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Older patients/older donors: choosing wisely

1 reference

https://pubmed.ncbi.nlm.nih.gov/32133897

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Conditioning regimens for hematopoietic cell transplantation: one size does not fit all

1 reference

https://pubmed.ncbi.nlm.nih.gov/32133897

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/32133897

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/32133897

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine-Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic Dosing

1 reference

https://pubmed.ncbi.nlm.nih.gov/32133897

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Allogeneic Hematopoietic Stem Cell Transplantation after Conditioning Regimens with Fludarabine/melphalan or Fludarabine/busulfan for Patients with Hematological Malignancies: A Single-center Analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/32133897

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes

1 reference

https://pubmed.ncbi.nlm.nih.gov/32133897

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial).

1 reference

https://pubmed.ncbi.nlm.nih.gov/32133897

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of Conditioning with Fludarabine/Busulfan and Fludarabine/Melphalan in Allogeneic Transplantation Recipients 50 Years or Older

1 reference

https://pubmed.ncbi.nlm.nih.gov/32133897

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity

1 reference

https://pubmed.ncbi.nlm.nih.gov/32133897

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q90059956&oldid=1559559391"